| 抗血管生成药物的研究进展与临床应用 |
| |
| 引用本文： | 尤燕,牟卫伟. 抗血管生成药物的研究进展与临床应用[J]. 食品与药品, 2021, 0(1): 92-96,后插1 |
| |
| 作者姓名： | 尤燕 牟卫伟 |
| |
| 作者单位： | 正大天晴药业集团股份有限公司;烟台市食品药品检验检测中心 |
| |
| 摘 要： | 血管生成(angiogenesis)在恶性肿瘤和视网膜病变等疾病过程中发挥着重要作用.随着血管新生的调节机制逐渐被揭示,抗血管生成药物的研发也取得新的突破,目前成功获批上市的抗血管生成靶向药物已达十余种,主要包括小分子多靶点血管靶向药物、大分子单靶点血管靶向药物、内源性泛靶点血管靶向药物3类.本文对抗血管生成策略的理论...
|
| 关 键 词： | 血管生成 抗血管生成药物 小分子靶向药物 单抗药物 |
Research Progress and Clinical Application of Antiangiogenic Agents |
| |
| YOU Yan,MOU Wei-wei. Research Progress and Clinical Application of Antiangiogenic Agents[J]. Food and Drug, 2021, 0(1): 92-96,后插1 |
| |
| Authors: | YOU Yan MOU Wei-wei |
| |
| Affiliation: | (Chiatai Tianqing Pharmaceutical Group Co.,Ltd.,Lianyungang 222062,China;Yantai Centre for Food and Drug Control,Yantai 264670,China) |
| |
| Abstract: | Angiogenesis plays an important role in the course of diseases such as malignant tumors and retinopathy.With the gradual disclosure of the regulation mechanism of angiogenesis,new breakthroughs have also been made in the research and development of anti-angiogenic drugs.Currently,there are more than ten kinds of anti-angiogenic targeting drugs successfully approved for marketing,mainly including small molecule multi-target vascular targeting drugs,macromolecular single-target vascular targeting drugs,and endogenous pan-target vascular targeting drugs.This article reviews the theoretical basis of the anti-angiogenesis strategy,the development of related drugs in recent years,and its application in clinical treatment. |
| |
| Keywords: | angiogenesis anti-angiogenic drug small molecule targeting drug monoclonal antibody |
| 本文献已被 CNKI 维普 等数据库收录！ |
|
